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Abstract: The present study aims to investigate the associations between major adverse cardio- 11 
vascular events (MACE) and high-density lipoprotein (HDL) functionality in patients who have 12
undergone coronary computed tomography angiography (CCTA). We performed a prospective 13
cohort study and enrolled 151 patients who underwent CCTA and had a follow-up of up to 5 years. 14
We measured cholesterol efflux capacity (CEC), caspase-3/7 activity and monocyte chemoattract- 15 
ant protein-1 (MCP-1) secretion as bioassays of HDL functionality. The patients were divided into 16
MACE(-) (n=138) and MACE(+) (n=13) groups. While there was no significant difference in %CEC, 17
caspase-3/7 activity and MCP-1 secretion between the MACE(-) and MACE(+) groups, total CEC 18
and HDL cholesterol (HDL-C) in the MACE(+) group were significantly lower than those in the 19
MACE(+) group. Total CEC was positively correlated with HDL-C, whereas %CEC showed no 20
correlation. In a logistic regression analysis, MACE was independently associated with total CEC 21
or HDL-C. Finally, a receiver- operating characteristic curve analysis indicated that there was no 22
significant difference between the areas under the curves for total CEC and HDL-C. Total CEC, 23
which depended on HDL-C levels, was significantly correlated with the presence of MACE. On the 24
other hand, %CEC was not associated with MACE.. 25 
Keywords: high-density lipoprotein; cholesterol efflux capacity; major adverse cardiovascular 26
events. 27 
 28 
1. Introduction 29 
In patients who are treated for atherosclerotic cardiovascular disease (ASCVD), 30
there is a possibility of some residual risks even when the low-density lipoprotein cho- 31 
lesterol (LDL-C) level has been significantly reduced [1] . Such residual risks include 32
when the triglyceride (TG) levels are high, the high-density lipoprotein cholesterol 33
(HDL-C) level is low and other uncontrolled risk factors are present [1-6] . A recent study 34
in a Japanese cohort indicated that extremely high HDL-C (≥90 mg/dL) had an adverse 35
effect on ASCVD mortality [7] . HDL mainly enhances reverse cholesterol transport such 36
as cholesterol efflux capacity (CEC), as well as having anti-oxidative, anti-inflammatory 37
and anti-apoptosis functions [8-10] . Recently, it has been considered that HDL quality as 38
well as HDL quantity is important for preventing CVD. Prospective studies revealed that 39
CEC was inversely associated with the incidence of CV events [11] . We also reported that 40
the restenosis rates after coronary stent implantation were associated with CEC [12] . 41
Thus, HDL functionality is a critical residual risk factor for ASCVD.  42 
Coronary computed tomography angiography (CCTA) has become more widely 43
available in many general hospitals and enables the accurate non-invasive assessment of 44
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coronary artery stenosis for screening of coronary artery disease (CAD). In our previous 45
cross-sectional study, high levels of HDL-C at the time of CCTA were associated with a 46
reduced presence and severity of CAD [13] . In addition, total CEC and HDL-C were as- 47 
sociated with the presence of CAD, while %CEC was not [14] . However, that study did 48
not analyze the associations between various HDL functionality including CEC and 49
prognosis. 50 
2. Materials and Methods 51 
In our previous study, 204 consecutive subjects who underwent CCTA for screening 52
of CAD and either were clinically suspected to have CAD or had at least one cardiovas- 53 
cular risk factor were enrolled and CEC was measured [14]. In this study, we excluded 53 54
of those patients due to the absence of follow-up and an insufficient volume of blood 55
sample, and finally analyzed HDL functionality in 151 patients.  56 
We followed the patients for up to 5 years (average, 3.7±0.7 years) and divided the 57
patients into those with [(+) group, n=13] and without [(-), n=138] MACE, where MACE 58
was defined as cardiovascular death, acute myocardial infarction, coronary revasculari- 59 
zation and ischemic stroke. When the patients had significant coronary stenosis as as- 60 
sessed by CCTA and received coronary intervention immediately after CCTA, the inter- 61 
vention was not included in MACE as coronary revascularization. We measured HDL 62
functionality including CEC, caspase 3/7 activity associated with apoptosis and the se- 63 
cretion of monocyte chemotactic protein-1 (MCP-1) associated with inflammation. The 64
protocol in this study was approved by the ethics committee of Fukuoka University 65
Hospital (# 09-10-02). All subjects gave their written informed consent to participate. 66 
                              67 
                             2.1. Evaluation of coronary stenosis using CCTA 68 
We evaluated coronary stenosis using CCTA as previously described. Briefly, all 69
patients were scanned by 64-multidetector row CT on an Aquilion 64 (TOSHIBA, Tokyo, 70
Japan). The region of interest was placed within the ascending aorta, and the scan was 71
started when the CT density reached 100 Hounsfield Units higher than the baseline CT 72
density. The scan was performed between the tracheal bifurcation and the diaphragm. 73
All segments were assessed according to the 15-segment American Heart Association 74
coronary artery model. Overall, 15 coronary artery segments were assessed in all patients. 75 
CAD was defined as any narrowing of the normal contrast-enhanced lumen to ≥50 % in 76
at least 1 major coronary artery that could be identified in multi-planar reconstructions or 77
cross-sectional images. 78 
 79 
2.2. Evaluation of CAD risk factors 80 
Age, gender, body mass index (BMI), systolic blood pressure (SBP), diastolic BP 81
(DBP), serum levels of LDL-C, HDL-C, triglycerides (TG), hemoglobin A1c (HbA1c), 82
fasting blood glucose (FBG), smoking status (current vs. nonsmoker), family history 83
[myocardial infarction (MI), angina pectoris or sudden death] and chronic kidney disease 84
(CKD) were collected as risk factors for CAD in all patients. BMI was calculated as weight 85
(kg)/height (m 2 ). BP was determined as the mean of two measurements obtained in an 86
office setting by the conventional cuff method using a mercury sphygmomanometer after 87
at least 5 min of rest. The characteristics of the patients with regard to history of hyper- 88 
tension (HTN), dyslipidemia (DL), diabetes mellitus (DM) and medication use were ob- 89 
tained from medical records. Patients who had a current SBP ≥140 mmHg and/or DBP 90
≥90 mmHg or who were receiving antihypertensive therapy were considered to have 91
HTN. Patients with LDL-C ≥140 mg/dl, TG ≥ 150 mg/dl, and/or HDL-C &lt;40 mg/dl or 92
who were receiving lipid-lowering therapy were considered to have DL. Patients with 93
FBG ≥ 126 mg, HbA1c ≥6.5 % or who were taking a glucose-lowering drug were consid- 94 
ered to have DM. We used estimated glomerular filtration rate (eGFR) calculated from 95
the results of serum creatinine, age, body size and gender. We defined CKD as when 96
eGFR was less than 60mL per minute per 1.73m 2 body surface area. 97 
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                             2.4. Measurement of HDL CEC 98 
We examined HDL CEC with an ex vivo system that used J774 macrophages and 99
HDL isolated from plasma of the study participants by ultracentrifugation as previously 100
described [14]. Briefly, J774 macrophages were cultured and radiolabeled with 2 µCi/ml 101
of 3 H-cholesterol for 24 h. The day after labeling, the cells were washed and incubated 102
with 8-Br-cAMP to upregulate ATP-binding cassette A1 transporter. Efflux medium 103
containing isolated HDL (15µg) was added for 4 h. Radiolabeled cholesterol counts were 104
measured for the cell compartment and media. The percentage (%) of CEC was calculated 105
by the following formula: [radioactivity in the medium/total radioactivity (radioactivity 106
in medium + cells extracted with NaOH/NaCl)] x 100 - CEC in sample-free medium. Total 107
CEC (T-CEC) was also calculated as the percentage of cholesterol efflux capacity/100 x 108
HDL-C level. 109 
 110 
2.5. Measurement of secretion of MCP-1 111 
We evaluated HDL-induced secretion of MCP-1 with an ex vivo system that used 112
human coronary endothelial cells (HCECs, Clonetics, San Diego, CA) [15] and 113
apo-B-depleted plasma from the study participants as samples. HCECs were cultured 114
and grown in media. In the experiments, HCECs were washed with medium. The cells 115
were incubated with 5 µg/ml of samples under the same conditions for 24 h. After 24 h, 116
the secretion of MCP-1 in the medium from HCECs was measured by Human 117
CCL2/MCP-1 Quantikine ELISA Kit (R & amp; D Systems, Minneapolis, MN). The rela- 118 
tive secretion of MCP-1 in each sample was calculated by the ratio of the secretion in each 119
sample to the secretion in standard HDL (EMD Millipore Corp., Billerica, MA). Relatively 120
total secretion of MCP-1 was also calculated as the relative secretion of MCP-1/100 x 121
HDL-C level. 122 
                              123 
                             2.6. Measurement of caspase 3/7 activity 124 
We analyzed HDL-suppressed caspase 3/7 activity with an ex vivo system that used 125
the H9C2 cell line of embryonic rat cardiomyoblasts (ATCC ® , CRL-1446 TM , Manassas, 126
VA) and apo-B-depleted plasma from the study participants as samples. H9C2 cells were 127
cultured and grown in media. In the experiments, H9C2 cells were grown under se- 128 
rum-free conditions for 2 h. After 2 h, the cells were incubated with 5 µg/ml of samples 129
for an additional 6 h. The caspase 3/7 activities in the H9C2 cells were measured by 130
Caspase-Glo ® 3/7Assay System (Promega Corp., Madison, WI). Relative caspase 3/7 ac- 131 
tivity in each sample was calculated by the ratio of the activity in each sample to the ac- 132 
tivity in standard HDL. Relatively total caspase 3/7 activity was also calculated as the 133
relative caspase 3/7 activity/100 x HDL-C level. 134 
 135 
2.7. Statistical analysis 136 
The statistical analysis was performed using IBM SPSS statistics software, version 22 137
(SPSS Inc., Chicago, IL) and EZR, which is for R (The R Foundation for Statistical Com- 138 
puting, Vienna, Austria). More precisely, it is a modified version of R Commander de- 139 
signed to add statistical functions frequently used in biostatistics [16]. Continuous varia- 140 
bles are shown as mean ± standard deviation. Categorical and continuous variables were 141
compared between the groups by a Chi-square analysis and t test, respectively. When 142
continuous variables did not show a normal distribution expressed as a median value 143
and interquartile range, we performed a Wilcoxon rank-sum test. The Spearman rank 144
correlation coefficient was used to evaluate associations between the groups. We used a 145
multiple logistic regression analysis for the multivariate analysis to evaluate independent 146
predictors of MACE and selected traditional coronary risk factors and total CEC or 147
HDL-C levels as independent variables. A receiver-operating characteristic (ROC) curve 148
analysis was used to determine the cut-off of the total cholesterol capacity or HDL-C to 149
distinguish between with and without MACE at the highest possible sensitivity and 150
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specificity levels. Area under the curve (AUC) values were compared between total CEC 151
and HDL-C by a Chi-square analysis. A value of p<0.05 was considered significant. 152 
 153 
3. Results 154 
3.1. Patient characteristics in all patients, and in the MACE(+) and MACE(-) groups 155 
Table 1 shows the patient characteristics in all patients, and in the MACE(+) and 156
MACE(-)groups. The mean age was 65 (58-71) years and BMI was 23±3 kg/m2 in all pa- 157 
tients. The frequencies of HTN, DL and DM in all patients were 78 %, 71 % and 23 %, 158
respectively. The MACE(+) group showed a higher level of %smoking and a lower level 159
of HDL-C than the MACE(-) group. There were no significant differences in other factors 160
including medications between the MACE(+) and MACE(-) groups. 161 
 162 
Table1. Patient characteristics in all patients, in the MACE(+), and MACE(-) groups. 163 
 164 
MACE major adverse cardiovascular events, BMI body mass index, HTN hypertension, SBP systolic blood pressure, DBP diastolic 165
BP, DL dyslipidemia, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, TG tri-glyceride, 166 
TC total cholesterol, DM diabetes mellitus, HbA1c hemoglobin A1c, FBG  fasting blood glucose, CAD coronary artery disease, 167 
ARB/ACE-I angiotensin II receptor blocker/angiotensin converting enzyme inhibitor, CCB calcium channel blocker, EPA eicosa- 168 
pentaenoic acid, DPP4-I dipeptidyl peptidase-4-inhibitor. *p<0.05 vs. MACE(-) group. 169 
ALL patients (n=151) MACE(+) (n=13) MACE(-) (n=138)
Age(years) 65(58-71) 67(58-70) 64(58–71)
Male(%) 62 62 57
BMI(kg/m2) 23±3 23±4 23±3
Smoking(%) 39 62* 34
HTN(%) 78 77 71
  SBP(mmHg) 134(123-146) 136(123-146) 133(123-146)
  DBP(mmHg) 76±12 79±19 76±11
DL(%) 71 77 64
  LDL-C(mg/dl) 108±28 94±28 109±28
  HDL-C(mg/dl) 50(43–61) 46(33–50)* 51(44-62)
  TG(mg/dl) 114(79-159) 113(76-187) 114(79-156)
DM(%) 23 23 21
  HbA1c(%) 5.6(5.3-6.2) 5.8(5.4-6.6) 5.6(5.3–6.2)
  Random BG 101(93-114) 101(93-124) 101(93-114)
Medication
  ARB/ACE-I(%) 44 46 41
  CCB(%) 35 31 33
  β-blocker(%) 17 0 17
  Diuretic(%) 13 15 12
  Statin(%) 34 46 35
  Fibrate(%) 0 0 0
  Ezetimib(%) 0 0 0
  EPA(%) 2 8 2
  Insulin(%) 10 8 6
  Sulfonylurea(%) 13 23 12
  Biguanide(%) 10 23 9
  DPP4-I(%) 10 15 9
Table1. Patient characteristics in all patients, in the MACE(+), and MACE(-) groups.
*p<0.05 vs. MACE(-) groupHTN, hypertension
J. Clin. Med. 2021, 10, 2431 5 of 10 
 
 
            170 
3.2. %CEC, total CEC and HDL-C in the MACE(+) and MACE(-) groups 171 
As shown in Figure 1A-C, the MACE(+) group showed significantly lower total CEC 172
(p=0.030) and HDL-C levels (p=0.014) than the MACE(-) group, while there was no dif- 173 
ference in %CEC between the groups. 174 
 175 
Figure1. (A)%CEC, (B) total CEC and (C) HDL-C in the MACE(+) and MACE(-) groups 176 
 177 
3.3. Relative caspase 3/7 activity, relatively total caspase 3/7 activity, the relative secretion of 178
MCP-1 and relatively total secretion of MCP-1 in the MACE(+) and MACE(-) groups 179 
Figure 2 shows caspase 3/7 activity and the secretion of MCP-1. There were no dif- 180 
ferences in relative caspase 3/7 activity (p=0.819), relatively total caspase 3/7 activity 181
(p=0.745), the relative secretion of MCP-1 (p=0.235) and relatively total secretion of 182
MCP-1 (p=0.307) between the groups. 183 
 184 
Figure2. (A) Relative caspase 3/7 activity, (B)relatively total caspase 3/7 activity, (C)the 185
relative secretion of MCP-1 and (D) relatively total secretion of MCP-1 in the MACE(+) and MACE(-) groups 186 
 187 
 188 
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3.4. Correlations between %CEC, total CEC and HDL-C in all patients 189 
Total CEC was positively correlated with HDL-C in all patients (r=0.793, p&lt;0.001), 190
whereas%CEC showed no correlation (r=0.024, p=0.769) (Figure 3AB). 191 
Figure3. Correlations between (A)%CEC, (B)total CEC and HDL-C in all patients 192 
 193 
3.5. Predictors of the presence of MACE in all patients 194 
Next, we analyzed the predictors of the presence of MACE in all patients using in- 195 
dependent variables by a logistic regression analysis (Figure 4AB). We selected tradi- 196 
tional coronary risk factors [age, gender (male), BMI, HTN, DL, DM, family history, 197
smoking and CKD] in addition to total CEC or HDL-C. MACE was independently asso- 198 
ciated with total CEC [Odds Ratio (OR):0.776, 95%Confidence Interval (CI): 0.60-0.96, 199
p=0.026] or HDL-C [OR: 0.930, 95%CI: 0.97-0.99, p=0.025]. 200 
Figure4. Predictors of the presence of MACE in all patients 201 




3.6. Cut-off values of total CEC or HDL-C levels for the diagnosis of MACE in all patients 203 
A ROC curve analysis showed that the AUC for total CEC and HDL-C were 0.682 204
and 0.696, respectively, in all patients (Figure 5AB). The cut-off levels of total CEC and 205
HDL-C that gave the greatest sensitivity and specificity for the presence of CAD were 206
12.4 (sensitivity 0.572, specificity 0.692) and 47 mg/dl (sensitivity 0.659, specificity 0.692), 207
respectively. There was no significant difference between the AUC for total CEC and 208
HDL-C (p=0.656), which indicated that these 2 factors contributed to MACE to a similar 209
extent. 210 
Figure5. Cut-off values of (A) total CEC or (B) HDL-C levels for the diagnosis of 211
MACE in all patients 212 
 213 
4. Discussion 214 
In this study, we hypothesized that HDL functionality, CEC in particular, was asso- 215 
ciated with MACE. The main finding was that total CEC and HDL-C were independent 216
predictors for MACE, while there was no difference in %CEC between the MACE(+) and 217
MACE(-) group. In addition, total CEC was correlated with HDL-C. These two factors 218
contributed to MACE to a similar extent. On the other hand, HDL functionality with re- 219 
gard to anti-inflammatory and anti-apoptosis effects were not associated with MACE. 220 
We showed that total CEC and HDL-C were significantly associated with MACE. 221
We measured %CEC using isolated HDL by ultracentrifugation to eliminate the effects of 222
other lipoproteins as much as possible, since several studies have reported that other 223
lipoproteins might influence cholesterol efflux capacity [17, 18] . By this method, we 224
could estimate the efflux capacity for a fixed amount of isolated HDL. This reflects the 225
effect of per unit capacity of HDL, but not total CEC in the bloodstream. There- 226 
fore, %CEC was normalized to total CEC in blood by the HDL-C concentration. Although 227
we used HDL without the effects of other lipoproteins to measure pure CEC, %CEC 228
values alone could not predict the occurrence of MACE. The involvement of other lipo- 229 
proteins, other than Apo-AI, was also considered. Since the MACE (+) group had signif- 230 
icantly lower HDL levels and the total CEC, which is the cholesterol uptake rate multi- 231 
plied by the HDL-C value, was associated with MACE, the HDL-C value itself was at 232
least related to MACE. In addition, since the correlation coefficient between HDL-C and 233
total CEC was 0.793, which is a relatively strong correlation, it may be possible to predict 234
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MACE from the HDL-C value without measuring total CEC. However, the HDL-C value 235
is 20-30% of the weight of HDL, and it is no clear whether the HDL-C value alone directly 236
reflects the functionality of HDL itself. In any case, these results show that both HDL 237
quality and quantity are important. In this study, the cut-off levels of total CEC and 238
HDL-C for the presence of MACE according to a ROC curve analysis were 12.4 and 47 239
mg/dl, respectively. To the best of our knowledge, only our previous report has ad- 240 
dressed the cut-off levels of total CEC [14] . In that study, the total CEC in the presence of 241
CAD was 12.2, which is similar to the value observed here. Next, the cut-off level of 242
HDL-C for the presence of MACE was 47 mg/dL, which is neither high nor low com- 243 
pared to values in the literature [6, 19] . The cut-off level of HDL-C for the diagnosis of 244
CAD was 48 mg/dl [14] , which is similar to the cut-off for the presence of MACE. These 245
results suggest that when patients show total CEC less than around 12.4 and/or HDL-C 246
less than around 47 mg/dL at the time of CCTA, they might develop MACE in the future. 247
According to the Japan Atherosclerosis Society Guidelines for Prevention of Atheroscle- 248 
rotic Cardiovascular Diseases 2017, serum HDL-C levels should be maintained ≥ 40 249
mg/dL for the primary and secondary prevention of CVD [6] . On the other hand, higher 250
levels of HDL-C have not been found to be associated with atheroprotection [7, 20-22] . In 251
NIPPON DATA90, high HDL-C (60-79 mg/dL) was associated with a significantly re- 252 
duced risk of CAD, whereas very high HDL-C (≥80 mg/dL) was not [22] . Recently, ex- 253 
tremely high levels of HDL-C (≥90 mg/dL) were significantly associated with an in- 254 
creased risk of ASCVD mortality, an increased risk of CAD and ischemic stroke in a 255
pooled analysis of Japanese cohorts (EPOCH-JAPAN) [7] . Thus, the cut-off level at 47 256
mg/dL of HDL-C, while relatively low, seems to be reasonable. 257 
HDL functionality with regard to anti-inflammation and anti-apoptosis was not as- 258 
sociated with MACE in this study. Many studies have shown that vascular inflammation 259
is associated with adverse events and C-reactive protein is a critical biomarker of CVD 260
[23-28] . MCP-1 is an inflammatory and apoptotic cytokine that is expressed mainly by 261
inflammatory cells and endothelial cells [29] . Caspase 3/7 activity also affects apoptosis. 262
They play a role in HDL functionality, and myocardial inflammation and apoptosis lead 263
to heart failure (HF). Chronic ischemic HF is associated with impaired HDL an- 264 
ti-oxidative capacity as well as reduced cholesterol efflux capacity [30, 31] . In addition, 265
HDL dysfunction promotes HF in Scarb1-deficient mice lacking SR-BI protein expression, 266
whereas restoration of HDL function following adeno-associated viral SR-BI gene trans- 267 
fer inhibits HF [32, 33] . Thus, HDL dysfunction is significantly associated with the pro- 268 
gression of HF. In this study, we enrolled patients who underwent CCTA for screening of 269
CAD who were initially diagnosed with CAD. Therefore, patients need to have HF for a 270
long time, and our duration of follow-up may have been too short (average 3.7 years). 271
This HDL functionality with regard to HF might be associated with MACE after 272
long-term follow-up. 273 
This study has several important limitations. First, the sample size was relatively 274
small which limited our ability to determine significance, although we found that total 275
CEC clearly had a significant correlation with MACE. Second, the CEC assay itself has 276
several limitations because cell-based assays are labor-intensive. Third, we divided pa- 277 
tients according to the presence of MACE and the duration of follow-up was only up to 278
five years. A large-scale survey with a longer follow-up and further analysis will be 279
needed. 280 
5. Conclusions 281 
HDL functionality with total CEC that was dependent on the HDL-C level was sig- 282 
nificantly correlated with the presence of MACE. On the other hand, %CEC, an- 283 
ti-inflammatory and anti-apoptosis effects were not associated with MACE. 284 
 285 
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